These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 31284866)

  • 1. Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it.
    Padilla-Martínez EM; Romero-Sanchez C; Bello-Gualtero JM; Mesa-Betancourt AM; Bautista-Molano W; Valle-O R
    Curr Rheumatol Rev; 2019; 15(4):329-335. PubMed ID: 31284866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No Correlation between Anti-drug Antibodies and Therapeutic Response in Tunisian Patients with Chronic Inflammatory Diseases Treated by TNF Blockers.
    Bouden S; Laadhar L; Soua J; Ben Messaoud M; Rouached L; Ayadi I; Saidane O; Ben Tekaya A; Mahmoud I; Rekik S; Srairi HS; Tekaya R; Bellakhal S; Fekih M; Abdelmoula L; Kallel M
    Curr Rheumatol Rev; 2024; 20(4):435-443. PubMed ID: 38314598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.
    Michelsen B; Fiane R; Diamantopoulos AP; Soldal DM; Hansen IJ; Sokka T; Kavanaugh A; Haugeberg G
    PLoS One; 2015; 10(4):e0123582. PubMed ID: 25853482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
    Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
    Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
    Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
    PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevalence and clinical effect of immunogenicity of TNF-α blockers in patients with axial spondyloarthritis.
    Bornstein G; Lidar M; Langevitz P; Fardman A; Ben-Zvi I; Grossman C
    Clin Exp Rheumatol; 2018; 36(2):228-232. PubMed ID: 29185966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis.
    Senabre Gallego JM; Rosas J; Marco-Mingot M; García-Gómez JA; Santos-Soler G; Salas-Heredia E; Pons-Bas A; Barber-Vallés X; Bernal-Vidal JA; Cano-Pérez C; García-Carrasco M; Flores-Pardo E;
    Rheumatol Int; 2019 May; 39(5):841-849. PubMed ID: 30899987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients.
    Arstikyte I; Kapleryte G; Butrimiene I; Venalis A
    Biomed Res Int; 2015; 2015():604872. PubMed ID: 26064930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database.
    Scirè CA; Caporali R; Sarzi-Puttini P; Frediani B; Di Franco M; Tincani A; Sinigaglia L; Sfriso P; Tirri R; Bellis E; Delsante G; Porru G; Salaffi F; Giuggioli D; Rossini M; Todoerti M; Bazzichi L; Govoni M; Gerli R; Raschetti R; Minisola G; Montecucco C; Todesco S;
    Clin Exp Rheumatol; 2013; 31(6):857-63. PubMed ID: 23981363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-drug antibodies and low serum trough infliximab levels correlate with disease activity measures in spondyloarthritis patients on an as-needed infliximab treatment.
    Patil A; Upadhyaya S; Dawar R; Dadhaniya N; Sood I; Gupta SJ; Handa R
    Int J Rheum Dis; 2019 Sep; 22(9):1638-1643. PubMed ID: 31211501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
    Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study.
    de la Torre I; Valor L; Nieto JC; Montoro M; Carreño L
    Reumatol Clin; 2014; 10(2):101-4. PubMed ID: 24280444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-neutralizing Antibodies against TNF-α blockers as Biomarkers of Therapy Effect Evaluation.
    Kraev K; Geneva-Popova M; Popova V; Popova S; Maneva A; Batalov A; Stankova T; Delcheva G; Stefanova K
    Folia Med (Plovdiv); 2020 Jun; 62(2):282-289. PubMed ID: 32666748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
    Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA
    Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical Aspects of Biological Throught Levels and Antidrug Antibodies in Rheumatoid Arthritis and Spondyloarthritis.
    Rosas J; Martín-López M; Otón T; Balsa A; Calvo-Alén J; Sanmartí R; Tornero J; Carmona L
    Reumatol Clin (Engl Ed); 2020; 16(5 Pt 2):378-385. PubMed ID: 30385295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
    Balsa A; Sanmarti R; Rosas J; Martin V; Cabez A; Gómez S; Montoro M
    Rheumatology (Oxford); 2018 Apr; 57(4):688-693. PubMed ID: 29365183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritis.
    Escudero-Vilaplana V; Ramírez-Herraiz E; Trovato-López N; Alañón-Plaza E; Bellini MJ; Herranz-Alonso A; Bellón-Cano JM; Morell-Baladrón A; Sanjurjo-Sáez M
    J Pharm Pharm Sci; 2012; 15(3):355-60. PubMed ID: 22974785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
    Al-Gareeb AIA; Gorial FI; Mahmood AS
    Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
    Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
    J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive clinical-genetic model of long-term non-response to tumor necrosis factor-alpha inhibitor therapy in spondyloarthritis.
    Polo Y La Borda J; Campos J; Sanz J; Andréu JL; Mulero J; Sánchez A
    Int J Rheum Dis; 2019 Aug; 22(8):1529-1537. PubMed ID: 31119895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.